This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The purpose of this research is to determine if there are differences in the amount of Ritalin or Focalin absorbed depending on whether alcohol is also administered. Recently, an MUSC study has found that when the prescription Attention Deficit/Hyperactivity Disorder (ADHD) medication Ritalin (generically called dl-methylphenidate) is combined with a drink containing ethyl alcohol (drinking alcohol), the alcohol increases the amount of Ritalin absorbed from the gut into the bloodstream. Also, humans were found to form a Ritalin -alcohol product called ethylphenidate. The Drug Enforcement Administration classifies both Ritalin , and the pure d-isomer form of methylphenidate marketed as Focalin (generically called dexmethylphenidate), as Schedule II drugs. This means that these drugs have a high abuse potential while still being recognized as possessing beneficial medical uses, e.g., to treat ADHD. Further, the extent of ethylphenidate formation will be established, as well as potential differences between men and women.
Showing the most recent 10 out of 395 publications